Avalo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Avalo Therapeutics Inc AVTX.OQ reported a quarterly adjusted loss of $1.92​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-14.07. The mean expectation of six analysts for the quarter was for a loss of $1.40 per share. Wall Street expected results to range from $-2.02 to $-1.20 per share.

• Reported revenue was zero​; analysts expected zero.

• Avalo Therapeutics Inc's reported EPS for the quarter was a loss of $1.92​.

• The company reported a quarterly loss of $20.77 million.

• Avalo Therapeutics Inc shares had risen by 79.0% this quarter and gained 20.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Avalo Therapeutics Inc is $35.00, about 74.5% above its last closing price of $8.93

This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)